Biogen

Why trials sponsored by Biogen stopped, in this sample of ClinicalTrials.gov.

16 stopped trials with a clear reason; 81% ended for non-scientific reasons.

Where it ranks

• #4 of 90 sponsors by share of trials stopped for: funding or business decisions (56%).

Among ranked sponsors in this sample. Shares of stopped trials, not failure rates. See all scorecards.

Trials

• 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
  NCT03070132 · WITHDRAWN · funding business
  “Sponsor Decision”
• A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants
  NCT05701423 · TERMINATED · slow accrual
  “Due to low enrolment the sponsor decided to terminate the study”
• Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
  NCT04106050 · WITHDRAWN · funding business
  “Sponsor Decision”
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease
  NCT03716570 · TERMINATED · futility
  “Affiliated study NCT03318523 did not meet its primary outcome measure of change from baseline measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and did not demonstrate efficacy on secondary outcome measures”
• Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy
  NCT03339336 · TERMINATED · funding business
  “Sponsor decision to close study early; not due to safety concerns”
• Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
  NCT03068130 · TERMINATED · logistics pi
  “The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.”
• A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
  NCT02855411 · TERMINATED · funding business
  “Terminated prematurely Sept 22, 2016 following an internal portfolio prioritization. It is not due to any safety concern or change in benefit:risk assessment.”
• Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
  NCT02658916 · TERMINATED · futility
  “251PP301(NCT03068468) primary endpoint was not met;further development of Gosuranemab BIIB092 in progressive supranuclear palsy will not be pursued.”
• Fampridine Pregnancy Exposure Registry
  NCT01532154 · TERMINATED · slow accrual
  “Due to low enrollment, registration closed in agreement with the Regulatory Agency”
• Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.
  NCT02343159 · TERMINATED · funding business
  “Sponsor Decision”
• Natalizumab Subcutaneous Immunogenicity and Safety Study
  NCT02142192 · TERMINATED · funding business
  “Sponsor's decision.”
• Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
  NCT02241785 · TERMINATED · funding business
  “Business Decision”
• A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
  NCT01500798 · TERMINATED · safety
  “IDMC recommendation for safety concerns”
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
  NCT01058005 · TERMINATED · slow accrual
  “Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study.”
• Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
  NCT00529113 · TERMINATED · funding business
  “To pursue other indications”
• Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
  NCT00298272 · TERMINATED · funding business
  “Sponsor decided to end long term extension phase for business reasons unrelated to safety.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.